Compare YHC & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YHC | NEUP |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 21.7M |
| IPO Year | N/A | N/A |
| Metric | YHC | NEUP |
|---|---|---|
| Price | $0.92 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 181.6K | 33.0K |
| Earning Date | 11-14-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,103,341.00 | ★ $15,649,448.00 |
| Revenue This Year | $69.97 | N/A |
| Revenue Next Year | $403.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.68 | $3.65 |
| 52 Week High | $98.00 | $21.40 |
| Indicator | YHC | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 45.06 |
| Support Level | $0.80 | $3.98 |
| Resistance Level | $0.95 | $4.11 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 56.74 | 19.35 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.